BeOne Medicines AG (ONC)
BeOne Medicines AG (ONC) carries a ŷRobot AI score of 51 out of 100. The model's fair value estimate is $412.06, 1.1% below the last close of $416.54. The chart signal reads Bearish.
| Metric | ONC |
|---|---|
| AI score | 51 / 100 |
| Chart signal | Bearish |
| Fair value estimate | $412.06 |
| Upside to fair value | -1.1% |
| Previous close | $416.54 |
| P/E | 69.28 |
| Price / sales | 6.63 |
| Market cap | $47.51B |
| EPS | 5.59 |
| Revenue growth | 40.3% |
| 1-year price change | -0.9% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about ONC
Is ONC overvalued or undervalued right now?
As of Nov 6, 2026, ŷRobot's fair-value model estimates BeOne Medicines AG (ONC) at $412.06 against a last close of $416.54, implying 1.1% downside to the model's estimate.
Is ONC's chart signal bullish or bearish?
The chart-signal model classifies ONC as Neutral as of Nov 13, 2026, with a signal score of -0.10 on a -1 to 1 scale.
What is ONC's ŷRobot AI score?
ONC scores 51 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 13, 2026.
Is ONC stock expensive on P/E and P/S?
ONC trades at 69.3 times earnings and 6.6 times sales as of Nov 13, 2026.
What does ONC's seasonal forecast show?
ŷRobot's seasonal forecast curve for ONC reads -4.1% at 30 days, -2.6% at 90 days, and -0.9% at one year as of Nov 13, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is ONC growing?
BeOne Medicines AG's revenue growth is +40.3% and free-cash-flow growth is +45.1% on the latest reported figures.
ONC chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.